APA (7th ed.) Citation

JM, L., S, B., VF, B., LG, A., K, P., I, B., . . . AP, B. (2023). The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank. Frontiers in immunology, 14, 1220129. https://doi.org/10.3389/fimmu.2023.1220129

Chicago Style (17th ed.) Citation

JM, Lonie, et al. "The Oesophageal Adenocarcinoma Tumour Immune Microenvironment Dictates Outcomes with Different Modalities of Neoadjuvant Therapy - Results from the AGITG DOCTOR Trial and the Cancer Evolution Biobank." Frontiers in Immunology 14 (2023): 1220129. https://doi.org/10.3389/fimmu.2023.1220129.

MLA (9th ed.) Citation

JM, Lonie, et al. "The Oesophageal Adenocarcinoma Tumour Immune Microenvironment Dictates Outcomes with Different Modalities of Neoadjuvant Therapy - Results from the AGITG DOCTOR Trial and the Cancer Evolution Biobank." Frontiers in Immunology, vol. 14, 2023, p. 1220129, https://doi.org/10.3389/fimmu.2023.1220129.